Blog Band - Page 101 of 264 - PharmaShots

Skip to content Skip to footer

Login orRegister

Veralox Therapeutics to Acquire Nudge Therapeutics, Expanding its Portfolio

Veralox Therapeutics to Acquire Nudge Therapeutics, Expanding its Portfolio

BySenior EditorJanuary 10, 20250Comments

Astellas Reports the Health Canada’s Approval of Vyloy (Zolbetuximab) Plus Chemotherapy for Advanced G/GEJ Cancer

ByRidhi RastogiJanuary 10, 20250Comments

J&J

Johnson & Johnson Reports the US FDA’s BLA Acceptance of Nipocalimab with Priority Review for Generalized Myasthenia Gravis (gMG)

ByRidhi RastogiJanuary 10, 20250Comments

Boehringer Ingelheim Licenses Synaffix’s Technology to Boost its ADC Portfolio in Oncology

Boehringer Ingelheim Licenses Synaffix’s Technology to Boost its ADC Portfolio in Oncology

BySenior EditorJanuary 10, 20250Comments

Bayer

Bayer Reports Topline Data from P-III (OASIS 4) Study of Elinzanetant to Treat Vasomotor Symptoms (VMS) Associated with Breast Cancer Therapies

ByRidhi RastogiJanuary 10, 20250Comments

Light Horse Therapeutics Partners with Novartis to Discover Therapies for Cancer Treatment

Light Horse Therapeutics Partners with Novartis to Discover Therapies for Cancer Treatment

BySenior EditorJanuary 10, 20250Comments

Transcarent to Acquire Accolade for ~$621M

Transcarent to Acquire Accolade for ~$621M

BySenior EditorJanuary 9, 20250Comments

MaaT Pharma Reports Topline Data from the Pivotal P-III (ARES) Trial of MaaT013 for Acute Graft-Versus-Host Disease

MaaT Pharma Reports Topline Data from the Pivotal P-III (ARES) Trial of MaaT013 for Acute Graft-Versus-Host Disease

BySenior EditorJanuary 9, 20250Comments

Vividion Therapeutics to Bolster its Genomic Abilities Through the Acquisition of Tavros Therapeutics

Vividion Therapeutics to Bolster its Genomic Abilities Through the Acquisition of Tavros Therapeutics

BySenior EditorJanuary 9, 20250Comments

Log in to your account